| Name | FUB-AMB |
|---|
| Formal Name | AMB-FUBINACA; methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate |
|---|
| SMILES | O=C(OC)C(NC(=O)c3nn(Cc1ccc(F)cc1)c2ccccc23)C(C)C |
|---|
| InChI Key | FRFFLYJQPCIIQB-SFHVURJKSA-N |
|---|
| InChI Code | InChI=1S/C21H22FN3O3/c1-13(2)18(21(27)28-3)23-20(26)19-16-6-4-5-7-17(16)25(24-19)12-14-8-10-15(22)11-9-14/h4-11,13,18H,12H2,1-3H3,(H,23,26)/t18-/m0/s1 |
|---|
| Description | FUB-AMB is an analogue of AB-FUBINACA, a potent synthetic cannabinoid first synthesized by Pfizer. AB-FUBINACA exhibits a strong affinity (Ki =0.9 nM) for the CB1 receptor. The primary amide moiety in the L-valinamide side chain in AB-FUBINACA is replaced with a methyl ester in FUB-AMB. FUB-AMB was identified by Louisiana crime labs in an herbal mixture labelled “Train Wreck2” in 2014 and was banned as a controlled dangerous substance as of July 3rd, 2014. The physiological and toxicological properties of this compound are not known. |
|---|
Status |
Verified |
|---|
| Submitted | 2015-10-01 |
|---|
| Submitted By | Cayman Chemical
Miami Valley Regional Crime Laboratory, Dayton, Ohio |
|---|
| Published | 2015-11-16 |
|---|
| Contact | Paul D. Kennedy, PhD. at Cayman Chemical |
|---|
| Product Details | Link |
|---|
Monograph |
Download the FUB-AMB Monograph |
|---|
|
|
